INS and diabetic retinopathy: This multicenter, randomized, controlled clinical trial involving 1441 subjects revealed reduced risks of diabetic retinopathy, nephropathy, neuropathy, and macrovascular disease in the cohort receiving intensive insulin treatment compared to standard therapy [28].